Aquestive Therapeutics AQST
$ 4.6
-2.85%
Quarterly report 2024-Q3
added 11-04-2024
Aquestive Therapeutics Balance Sheet 2011-2024 | AQST
Annual Balance Sheet Aquestive Therapeutics
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
21.5 M | 6.43 M | -25.2 M | 5.1 M | 11 M | -13.4 M | 28.1 M | 29.4 M | - | - | - | - | - |
Long Term Debt |
45 M | 33.4 M | 1.95 M | 34.3 M | 60.3 M | 42.6 M | 45.5 M | 38.6 M | - | - | - | - | - |
Long Term Debt Current |
390 K | 255 K | 899 K | 728 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 90.3 M | 66 M | 43.8 M | 54.3 M | 46.2 M | - | - | - | - | - |
Total Current Liabilities |
18.3 M | 39.5 M | 22 M | 21.1 M | 18.6 M | 33 M | - | - | - | - | - | - | - |
Total Liabilities |
164 M | 176 M | 144 M | 111 M | 84.6 M | 76.8 M | 69.6 M | 57 M | - | - | - | - | - |
Deferred Revenue |
1.55 M | 1.51 M | 765 K | 693 K | 806 K | 721 K | 1.35 M | 802 K | - | - | - | - | - |
Retained Earnings |
-319 M | -311 M | -257 M | -186 M | -130 M | -61.4 M | -120 M | -109 M | - | - | - | - | - |
Total Assets |
57.4 M | 57.1 M | 62 M | 62.9 M | 78.5 M | 86.9 M | 43.1 M | 39.4 M | - | - | - | - | - |
Cash and Cash Equivalents |
23.9 M | 27.3 M | 28 M | 31.8 M | 49.3 M | 60.6 M | - | - | - | - | - | - | - |
Book Value |
-106 M | -119 M | -82.1 M | -48.5 M | -6.12 M | 10.1 M | -26.5 M | -17.6 M | - | - | - | - | - |
Total Shareholders Equity |
-106 M | -119 M | -82.1 M | -48.5 M | -6.12 M | 10.1 M | -68.6 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Aquestive Therapeutics
2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
45 M | 45 M | 45 M | 14.8 M | 39 M | 39 M | 42.4 M | 5.08 M | 51.5 M | - | 51.5 M | 1.95 M | 51.5 M | 51.5 M | 51.5 M | 51.5 M | 70 M | 70 M | 70 M | 70 M | 70 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
155 M | 153 M | 166 M | 164 M | 162 M | 164 M | 171 M | 176 M | 160 M | - | 150 M | 144 M | 126 M | 121 M | 114 M | 111 M | 111 M | 111 M | 111 M | 84.6 M | 84.6 M | 84.6 M | 84.6 M | 76.8 M | 76.8 M | 76.8 M | 76.8 M | 69.6 M | 69.6 M | 69.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
1.05 M | 1.05 M | 1.55 M | 1.55 M | 2.64 M | 3.99 M | 4.76 M | 1.51 M | 774 K | - | 1.6 M | 765 K | 767 K | 642 K | 437 K | 693 K | 693 K | 693 K | 693 K | 806 K | 806 K | 806 K | 806 K | 721 K | 721 K | 721 K | 721 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-346 M | -335 M | -332 M | -319 M | -311 M | -309 M | -303 M | -311 M | -299 M | - | -270 M | -257 M | -228 M | -213 M | -201 M | -186 M | -186 M | -186 M | -186 M | -130 M | -130 M | -130 M | -130 M | -61.4 M | -61.4 M | -61.4 M | -61.4 M | -120 M | -120 M | -120 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
110 M | 118 M | 130 M | 57.4 M | 59.4 M | 57 M | 61.3 M | 57.1 M | 51.8 M | - | 56.5 M | 62 M | 65.3 M | 66.9 M | 61.9 M | 62.9 M | 62.9 M | 62.9 M | 62.9 M | 78.5 M | 78.5 M | 78.5 M | 78.5 M | 86.9 M | 86.9 M | 86.9 M | 86.9 M | 43.1 M | 43.1 M | 43.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
77.9 M | 89.9 M | 95.2 M | 23.9 M | 24.9 M | 22.4 M | 26.9 M | 27.3 M | 18.6 M | 17.7 M | 14.7 M | 28 M | 31.2 M | 34.2 M | 27.5 M | 31.8 M | 17.1 M | 31.8 M | 31.8 M | 49.3 M | 49.3 M | 49.3 M | 49.3 M | 60.6 M | 60.6 M | 60.6 M | 60.6 M | 17.4 M | 17.4 M | 17.4 M | - | 9.21 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
-45.4 M | -35.5 M | -36.3 M | -106 M | -103 M | -107 M | -109 M | -119 M | -108 M | - | -93.1 M | -82.1 M | -60.3 M | -53.8 M | -51.8 M | -48.5 M | -48.5 M | -48.5 M | -48.5 M | -6.12 M | -6.12 M | -6.12 M | -6.12 M | 10.1 M | 10.1 M | 10.1 M | 10.1 M | -26.5 M | -26.5 M | -26.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-45.4 M | -35.5 M | -36.3 M | -106 M | -103 M | -107 M | -109 M | -119 M | -108 M | -96.4 M | -93.1 M | -82.1 M | -60.3 M | -53.8 M | -51.8 M | -48.5 M | -48.5 M | -48.5 M | -48.5 M | -6.12 M | -6.12 M | -6.12 M | -6.12 M | 10.1 M | 10.1 M | 10.1 M | 10.1 M | -26.5 M | -68.6 M | -68.6 M | - | -57.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency